icon
موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية
icon السبت 13 جمادى الأولى 1448هـ
نسخة تجريبية
icon
روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
المواقع الرسمية الآمنة تستخدم HTTPS

تحقق من أن الموقع يستخدم بروتوكول HTTPS

icon

مسجل لدى هيئة الحكومة الرقمية برقم :

20250831619
اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 241 - 250 من 518
عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) Albireo Ongoing A4250 3 A4250-008 King Faisal Specialist Hospital and Research Center (Riyadh)
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) Pfizer Ongoing PF-06838435 3 C0371002 King Faisal Specialist Hospital and Research Center (Riyadh)
"ALL SCTped 2012 FORUMAllogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" KAIMRC Completed • BUSULFAN• FLUDARABINE PHOSPHATE• ETOPOSIDE 3 CT17/016/R King Abdulaziz Medical City NG (Riyadh)
Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. King Abdullah Medical City, Holy Capital Ongoing • PANITUMUMAB• OXALIPLATIN• irinotecan• FLOUROURACIL 2 19-504 King Abdullah Medical City (Makkah)
Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer King Faisal Specialist Hospital and Research Centre Ongoing • TOCILIZUMAB (ACTEMRA)• DOCETAXEL (TAXOTERE)• CISPLATIN 2a 2181156 King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension Biogen Ongoing Interferon beta-1a 3 105MS306 King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh)
"A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin" SANOFI Ongoing TOUJEO 4 LPS15396 Sultan bin Abdulaziz Humanitarian city (Riyadh)
"A multi-centre prospective non-interventional studyinvestigating the clinical effectiveness of Ryzodeg® (InsulinDegludec/Insulin Aspart) in patients with type 2 diabetesmellitus in a real-world setting" Novo Nordisk Ongoing Ryzodeg Flex Touch 4 NN54014525 King Abdulaziz University Hospital (Jeddah), Ghassan Najeeb Pharaon hospital (Jeddah), Saudi German Hospital (Jeddah), Umm Al-Qura University (Makkah), Dallah Hospital (Riyadh), Riyadh Care Hospital (Riyadh), Specialized Medical Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
A prospective Randomized study of General Anesthesia versus Anesthetist Administered sedation for ERCP King Abdullah Medical City (Makkah) Ongoing FENTANYL/ CISATRACURIUM/ SEVOFLURANE 4 18-492 King Abdullah Medical City (Makkah)
CRAD001H2406- A long-term non-interventional observational study in Living Donor Liver Transplant Recipients (LDLTRs) with primary hepatocellular carcinoma (HCC) treated with Certican® / Zortress® (everolimus; EVR) plus reduced tacrolimus (rTAC) versus standard tacrolimus (sTAC) control Novartis Ongoing • everolimus • reduced tacrolimus 4 CRAD001H24 King Faisal Specialist Hospital and Research Center (Riyadh)